Loading...
Loading...
AGRX| Name | Value |
|---|---|
| Revenues | 5,576.0K |
| Cost of Revenue | 1,496.0K |
| Gross Profit | 4,080.0K |
| Operating Expense | 6,826.0K |
| Operating I/L | -2,746.0K |
| Other Income/Expense | -9,126.0K |
| Interest Income | 28.0K |
| Pretax | -11,872.0K |
| Income Tax Expense | 0.0K |
| Net Income/Loss | -11,872.0K |
Agile Therapeutics, Inc. is a women's healthcare company specializing in the research, development, and commercialization of prescription contraceptive products in the United States. Its flagship product, Twirla (AG200-15), is a once-weekly combination hormonal contraceptive patch. The company also focuses on developing a pipeline of Twirla line extensions and other products, including AG200-15 Extended Regimen (ER) and AG200-15 smaller patch (SmP) to enhance contraceptive efficacy and provide shorter and lighter withdrawal bleeds. Additionally, Agile Therapeutics is working on P-Patch, a progestin-only contraceptive patch for women unable or unwilling to take estrogen.
